Emergence of RAS mutations in patients with metastatic colorectal cancer receiving cetuximab-based treatment: a study protocol

Table 1 Summary of studies monitoring RAS mutations in ctDNA of mCRC patients receiving anti-EGFR therapies

Reference	Methods for ctDNA measurement	Patients (n)	Previous chemotherapy exposure	Anti-EGFR therapy	Rate of detected circulating RAS mutations during treatment (%)	Potential clinical value
Diaz LA et al. [13]	BEAMing	28	yes	panitumumab	38	Circulating KRAS mutations generally occurred 5 to 6 months after anti-EGFR therapy.
Misale S et al. [14]	Pyrosequencing or BEAMing	10	yes	cetuximab or panitumumab	60	Circulating KRAS mutations were frequently detected in acquired resistance to anti-EGFR therapies.
Toledo RA et al. [30]	BEAMing	23	no	cetuximab	13	Abrupt increase in mutant cfDNA correlated with eminent clinical deterioration.
Vidal J et al. [31]	BEAMing	18	unknown	cetuximab or panitumumab	39	Circulating RAS mutations correlated with acquired resistance to anti-EGFR therapies.

ISSN: 1471-2407